Prevention of recurrences after deep venous thrombosis: Role of low- molecular-weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 1, 1997, Pages 51-54

  Pini, Mario ^a  

^a Ospedale di Fidenza   (Italy)

Author keywords

bleeding; Deep venous thrombosis; heparin; low molecular weight (LMW) heparin; oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; THROMBOSIS; VERTEBRA FRACTURE;

EID: 0030996056     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996070     Document Type: Conference Paper

References (18)

1. Brandjes DPM, H Heijboer, HR Büller, M de Rijk, H Jagt, JW ten Gate: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 327:1485-1489, 1992.
2. Levine MN, J Hirsh, S Landefeld, GE Raskob: Hemorrhagic complications of anticoagulant treatment. Chest 102 (Suppl): 353S-363S, 1992.
3. Palareti G, N Leali, S Coccheri, M Poggi, C Manotti, A D'Angelo, V Pengo, N Erba, M Moia, N Ciavarella, G Devoto, M Berettini: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (IS-COAT). Lancet 348:423-428, 1996.
4. Hull R, T Delmore, E Genton, J Hirsh, M Gent, D Sackett, D McLaughlin, P Armstrong: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301:855-858, 1979.
5. Hull R, J Hirsh, R Jay, C Carter, C England, M Gent, AGG Turpie, D McLaughlin, P Dodd, M Thomas, G Raskob, P Ockelford: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307: 1676-1681, 1982.
6. Hull R, T Delmore, C Carter, J Hirsh, E Genton, M Gent, G Turpie. D McLaughlin: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 306:189-194, 1982.
7. Monreal M, E Lafoz, A Olive, L del Rio, C Vedia: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemostas 71:7-11, 1994.
8. Pini M, S Aiello, C Manotti, C Pattacini, R Quintavalla, T Poli, A Tagliaferri, AG Dettori: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemostas 72:191-197, 1994.
9. Pini M, C Pattacini, R Quintavalla, T Poli, A Megha, A Tagliaferri, C Manotti, AG Dettori: Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis - A randomized clinical trial. Thromb Haemostas 64:222-226, 1990.
10. Marciniak E, JP Gockerman: Heparin-induced decrease in circulating antithrombin III. Lancet 2:581-584, 1977.
11. Prandoni P, AW Lensing, HR Büller, A Cogo, MH Prins, AM Cattelan, S Cuppini, F Noventa, JW ten Cate: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133, 1992.
12. Research Committee of the British Thoracic Society: Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340:873-876, 1992.
13. Levine M, J Hirsh, M Gent, AG Turpie, J Weitz, J Ginsberg, W Geerts, J LeClerc, J Neemeh, P Powers, F Piovella: Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal vein thrombosis. Thromb Haemostas 74:606-611, 1995.
14. Schulman S, AS Rhedin, P Lindmarker, A Carlsson, G Lärfars, P Nicol, E Loogna, E Svensson, B Ljungberg, H Walter, S Viering, S Norlander, B Leijd, KA Jönsson, M Hjorth, O Linder, J Boberg: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661-1665, 1995.
15. Petitti DB, BL Strom, KL Melmon: Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and haemorrhage. Am J Med 81:255-259, 1986.
16. Hirsh J: The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med 332:1710-1711, 1995.
17. Levine M, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, J Ginsberg, AG Turpie, C Demers, M Kovacs, W Geerts, J Kassis, L Desjardin, J Cusson, M Cruickshank, P Powers, W Brien, S Haley, A Willan: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996.
18. Koopman MMW, P Prandoni, F Piovella, PA Ockelford, DPM Brandjes, J van der Meer, A Gallus, G Simonneau, CH Chesterman, MH Prins, PMM Bossuyt, H de Haes, AGM van den Belt, L Sagnard, P d'Azemar, HR Büller: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334:682-687, 1996.